TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Nurses' satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Oswestry Disability index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean difference in block coverage of the posterior incision line
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of bleeding complications
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of thromboembolic events
Endpoint domain: Adverse events/effects
Primary endpoint: Subject-reported quality of vision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Limbal and conjunctival redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of intraoperative discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF caspase‐3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum caspase‐3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity for diagnosis of bacteremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in ulcerating disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of perianal abscesses
Endpoint domain: Adverse events/effects
Primary endpoint: total cumulative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: postoperative transfusion requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AAI response to surgical stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average difference in V(T)'
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effectiveness of noncontact method in stopping bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue damage caused by treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Data completeness
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: subsequent clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean rating scores assigned by physicians
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent cardiac arrest
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac transplantation
Endpoint domain: Mortality/survival
Primary endpoint: tongue motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biceps electromyographic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with VAS = 0 at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American College of Rheumatology 20% improvement criteria response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of whole-blood TXB2 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Urinary excretion of 11-dehydro-TXB2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Systemic prostacyclin biosynthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: WAnT average power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total metabolic energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMP-9 mRNA reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in mEASI and EASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of skin burning
Endpoint domain: Adverse events/effects
Primary endpoint: Ascorbate concentration in tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ascorbate concentration in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD34(+) cells peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: freedom from acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average IMT change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: First pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver reliability of neck mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Painfree walking distance (PFWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum walking distance (MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum high‐sensitivity C‐reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma brain natriuretic peptide (BNP) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: B-cell counts reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CCK release at 15 min following the meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hearing aid candidacy prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oropharyngeal swallowing efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency or severity of motor and vocal tics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse drug effects on cardiovascular function
Endpoint domain: Adverse events/effects
Primary endpoint: Growth at the end of 2 years of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: workday sitting time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: workday standing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced expiratory volume in 1 sec predicted (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak expiratory flow (PEF) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Symptom diary scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nuchal translucency MoMs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difficulty accessing ER strategies
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ADCS ADL scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean glycated hemoglobin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: complete surgical resection (R0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: time to local recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total CVD events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in prothrombin fragments 1+2 (F1+2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: gestational diabetes
Endpoint domain: Adverse events/effects
Primary endpoint: eGFR decline + ESRD
Endpoint domain: Mortality/survival
Primary endpoint: Subfoveal Choroidal Thickness (SFCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: percentage of slow wave sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apnoea hypopnoea index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Detection of DD3 mRNA in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Xerostomia persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal intercourse without a condom outside of a monogamous relationship
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sexual health outcomes
Primary endpoint: Condom use with a main male partner
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sexual health outcomes
Primary endpoint: Condom barriers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sexual health outcomes
Primary endpoint: Secure attachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term major adverse cardiac events
Endpoint domain: Mortality/survival
Primary endpoint: Sagittal plane translation during flexion-extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion at the L4/5 proximal adjacent level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial leptin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: decreased anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgical site infection incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Shear Bond Strength (SBS) of composite to enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute changes in depressive symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin hydration level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: barrier permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in post-brushing plaque scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: opioid use reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: false-negative rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transient rVSV viremia
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary continence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anastomotic operative time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time interval from induction to vaginal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal delivery rates within 12 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of fast ventricular tachyarrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vertical clinical attachment gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal clinical attachment gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical radiographic bone gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device placement failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to complete placement procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: stroke, myocardial infarction, or vascular death
Endpoint domain: Mortality/survival
Primary endpoint: clinical pregnancy rate
Endpoint domain: Mortality/survival
Primary endpoint: embryo implantation rate
Endpoint domain: Mortality/survival
Primary endpoint: Peak exposure (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total systemic exposure (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early exposure (AUC0-30 minutes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary function measurements (FEV1, FEV1 % pred, FVC, PEF, MEF50, MEF25)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sexual desire/drive
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: frequency of masturbation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: pornography use
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum Cr concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma NH3+ accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mood changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Selection of insurance plan matching tool's recommendations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduced occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced mucus accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced ETT-based biomass of bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Success rate of treatment
Endpoint domain: Mortality/survival
Primary endpoint: Mean duration prior to request for additional analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular-risk class increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ability to stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standing blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence rate of ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence rate of other cardiac complications
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients classified as responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of preference of medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Requirement for benzodiazepines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 6-month retention rate
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of urine samples free of illicit opiates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Problem severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median decrease in HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of alanine aminotransaminase and HBV DNA<300 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to FIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transferrin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety and tolerability of E7820
Endpoint domain: Adverse events/effects
Primary endpoint: Best response rate (SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean global health quality of life indicator scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hoogland score of 5 or 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean postoperative refractive sphere
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of corneal surface horizontal coma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: simulated driving safety performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progressive ratio breakpoint values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive subjective ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response to venlafaxine or lithium therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lens movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of needle advances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of successful cannulations on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of weight loss from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achieving partial or full remission of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: thrombosed internal hemorrhoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relax scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Symptomatic ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in left ventricular mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocaine craving scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psoriasis Area and Severity Index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean compression depth ≥ 40 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: compression rate 80-120/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequate mean ventilation volume (400-1000 ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in symptoms and signs of endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAT score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Additional weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in cardiovascular disease-risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC for glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sufficient range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in pain with motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate at 3 months postintervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glasgow Outcome Scale (GOS) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of IgM, IgG, total protein and serum albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: duration of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: neutrophil count after chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in AAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in clinical attachment level (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GEL concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C3a concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: visual acuity of 6/36 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corneal neovascular invasion area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increasing physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Transcutaneous oxygen tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes